Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | RAD52 | P43351 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | GAPDH | P04406 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23413275 | 0.89 | ADRA2B (0.45) | TAAR1ADRA2BMPO | |
| SCHEMBL26460682 | 0.88 | ADRA2B (0.47) | TAAR1ADRA2BKMT2AMEN1TDP1 | |
| SCHEMBL4332045 | 0.86 | ADRA2B (0.49) | TAAR1ADRA2BTDP1MAPTMAPK1 | |
| SCHEMBL17182626 | 0.85 | ADRA2B (0.45) | TAAR1ADRA2BKMT2AMEN1TDP1 | |
| SCHEMBL2384003 | 0.85 | ADRA2B (0.45) | TAAR1ADRA2BKMT2AMEN1RAD52 | |
| Hydrochloric Acid SCHEMBL1161200 | 0.84 | ADRA2B (0.47) | TAAR1ADRA2BKMT2AMEN1RAD52 | |
| Hydrochloric Acid SCHEMBL31716430 | 0.84 | ADRA2B (0.47) | TAAR1ADRA2BKMT2AMEN1RAD52 | |
| SCHEMBL31175766 | 0.83 | ADRA2B (0.50) | TAAR1ADRA2BKMT2AMEN1TDP1 | |
| SCHEMBL26037690 | 0.83 | ADRA2B (0.50) | TAAR1ADRA2BKMT2AMEN1TDP1 | |
| SCHEMBL1116576 | 0.81 | IDO1 (0.57) | TAAR1KMT2AMEN1RAD52RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027075-A1 | SULFONAMIDE COMPOUNDS TARGETING CD73 AND ADENOSINE RECEPTORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-01-26 | — | — | US | disclosed |
| EP-4065590-A1 | SULFONAMIDE COMPOUNDS TARGETING CD73 AND ADENOSINE RECEPTORS | Aurigene Discovery Technologies Limited (IN) | 2022-10-05 | — | — | EP | disclosed |
| CN-114728998-A | Sulfonamide compounds targeting CD73 and adenosine receptors | 奥瑞基尼探索技术有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021105916-A1 | SULFONAMIDE COMPOUNDS TARGETING CD73 AND ADENOSINE RECEPTORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-06-03 | — | — | WO | disclosed |
| WO-2010123017-A1 | TETRAZOLE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
| US-6534546-B1 | Guanidine- or isothioureido-N-derived anilines; brain, nervous system, and neurodegenerative disorders | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-18 | — | — | US | disclosed |
| CN-1075808-C | Aniline derivatives having nitric oxide synthase inhibitory activity | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2001-12-05 | — | — | CN | disclosed |
| CN-1310169-A | Anils with nitric oxide synzyme inhibiting function | SHUGAI SEIYAKU K K (JP) | 2001-08-29 | — | — | CN | disclosed |
| CN-1172473-A | Aniline derivatives having nitric oxide synthase inhibitory activity | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1998-02-04 | — | — | CN | disclosed |
| EP-0798292-A1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | Chugai Seiyaku Kabushiki Kaisha (JP) | 1997-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027075-A1 | SULFONAMIDE COMPOUNDS TARGETING CD73 AND ADENOSINE RECEPTORS | ADORA2A, ADORA2B, ENTPD5 | TAAR1 218/4885ADRA2B 249/4885KMT2A 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.